pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
PUBLIC COMPANY
save

$XERSXeris Biopharma Holdings, Inc.

$XERS9.2500-3.24%
Chicago, IL, USupdated 19h ago
SEC EDGAR ↗Yahoo Finance ↗
community read0 votes
pipeline
3
marketed
2
phase 3
0
catalysts ytd
1
approvals ytd
0
recalls ytd
0

Pipeline(3)

pipeline depth3 products
Phase 2: 1Marketed: 2
1Phase 22Marketed
Marketed
glucagon
Hypoglycemia
Marketed
levoketoconazole
Cushing's Syndrome
Phase 2
levothyroxine sodium
Hypothyroidism
Thyroid hormone receptor

📅 Upcoming

Nov 5, 2026
earnings
$XERS9.2500-3.24%
in 1mo
Xeris Biopharma Holdings, Inc. earnings
Xeris Biopharma Holdings, Inc.
→

🕒 Recent(90d)

nothing in the last 90 days
view all catalysts →

Active trials

  • phase2Glucagon Ready-to-Use (RTU) for Prevention of Exercise-Induced Hypoglycemia During Aerobic Exercise in Adults With T1Dcompletedn=48
  • phase2Study of XP-8121 For the Treatment of Adult Subjects With Hypothyroidismcompletedn=46
  • phase2Phase 2, Randomized, Open-Label, Crossover, PD/PK Study of a Novel Pram-Insulin Co-Formulation in Adults With T1Dcompletedn=18
🐶 Hiring Signal
next earnings Nov 5, 2026
No open roles indexed yet — view Xeris Biopharma Holdings, Inc. jobs →

News

no news has mentioned this company yet
identifiers
ticker
$XERS
SEC CIK
0001867096
country
US
source
sec_tickers
mentioned in
0news items
entity-linker matched
Data sources
SEC EDGAR
last refreshed 42m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?